Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant

被引:0
|
作者
T L Slatter
N Hung
S Bowie
H Campbell
C Rubio
D Speidel
M Wilson
M Baird
J A Royds
A W Braithwaite
机构
[1] Dunedin School of Medicine,Department of Pathology
[2] ,Department of Microbiology and Immunology
[3] University of Otago,undefined
[4] Children’s Medical Research Institute,undefined
[5] University of Sydney,undefined
[6] School of Medical Sciences,undefined
[7] University of Otago,undefined
[8] Maurice Wilkins Centre for BioDiscovery,undefined
[9] University of Otago,undefined
来源
Cell Death & Disease | 2015年 / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Growing evidence suggests the Δ133p53α isoform may function as an oncogene. It is overexpressed in many tumors, stimulates pathways involved in tumor progression, and inhibits some activities of wild-type p53, including transactivation and apoptosis. We hypothesized that Δ133p53α would have an even more profound effect on p53 variants with weaker tumor-suppressor capability. We tested this using a mouse model heterozygous for a Δ133p53α-like isoform (Δ122p53) and a p53 mutant with weak tumor-suppressor function (mΔpro). The Δ122p53/mΔpro mice showed a unique survival curve with a wide range of survival times (92–495 days) which was much greater than mΔpro/- mice (range 120–250 days) and mice heterozygous for the Δ122p53 and p53 null alleles (Δ122p53/-, range 78–150 days), suggesting Δ122p53 increased the tumor-suppressor activity of mΔpro. Moreover, some of the mice that survived longest only developed benign tumors. In vitro analyses to investigate why some Δ122p53/mΔpro mice were protected from aggressive tumors revealed that Δ122p53 stabilized mΔpro and prolonged the response to DNA damage. Similar effects of Δ122p53 and Δ133p53α were observed on wild-type of full-length p53, but these did not result in improved biological responses. The data suggest that Δ122p53 (and Δ133p53α) could offer some protection against tumors by enhancing the p53 response to stress.
引用
收藏
页码:e1783 / e1783
相关论文
共 50 条
  • [31] NEW TUMOR-SUPPRESSOR MAY RIVAL P53
    MARX, J
    SCIENCE, 1994, 264 (5157) : 344 - 345
  • [32] TUMORIGENESIS ASSOCIATED WITH THE P53 TUMOR-SUPPRESSOR GENE
    CHANG, F
    SYRJANEN, S
    TERVAHAUTA, A
    SYRJANEN, K
    BRITISH JOURNAL OF CANCER, 1993, 68 (04) : 653 - 661
  • [33] CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE
    RUTZ, HP
    MIRIMANOFF, RO
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12): : 864 - 865
  • [34] THE CLINICAL RELEVANCE OF THE P53 TUMOR-SUPPRESSOR GENE
    DOWELL, SP
    HALL, PA
    CYTOPATHOLOGY, 1994, 5 (03) : 133 - 145
  • [35] Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence
    Horikawa, Izumi
    Fujita, Kaori
    Jenkins, Lisa M. Miller
    Hiyoshi, Yukiharu
    Mondal, Abdul M.
    Vojtesek, Borivoj
    Lane, David P.
    Appella, Ettore
    Harris, Curtis C.
    NATURE COMMUNICATIONS, 2014, 5
  • [36] CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE
    HARRIS, CC
    HOLLSTEIN, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (18): : 1318 - 1327
  • [37] Mutant p53 activities in tumor development
    Lozano, Guillermina
    CLINICAL CANCER RESEARCH, 2016, 22
  • [38] IS P53 THE ONLY REAL TUMOR-SUPPRESSOR GENE
    BERNS, A
    CURRENT BIOLOGY, 1994, 4 (02) : 137 - 139
  • [39] TUMOR-SUPPRESSOR P53 AND THE CELL-CYCLE
    PERRY, ME
    LEVINE, AJ
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1993, 3 (01) : 50 - 54
  • [40] OVEREXPRESSION OF P53 TUMOR-SUPPRESSOR PROTEIN IN POROKERATOSIS
    MAGEE, JW
    MCCALMONT, TH
    LEBOIT, PE
    ARCHIVES OF DERMATOLOGY, 1994, 130 (02) : 187 - 190